ESMO – European Society for Medical Oncology shared on LinkedIn:
“Could your research contribute to the conversations shaping thoracic oncology?
Submit your abstract by 12 January and present your findings to an international, multidisciplinary community at ELCC27 in Munich.
The programme on Wednesday 17 March will explore some of the questions influencing current and future practice, including:
- How can first-line treatment decisions in advanced EGFR-mutant NSCLC be further personalised?
- What role could biomarkers play in guiding post-combination treatment choices?
- How are CAR T cells, TILs and cancer vaccines advancing thoracic oncology?
- Could BiTEs and TriTEs open new opportunities for immunotherapy?
Swipe through the images for a preview of the programme, and submit your research to help move the discussion forward.
Munich, Germany
17–20 March 2027․”
Other articles about ELCC27 on OncoDaily.